Theriva Biologics, Inc. Common Stock TOVX 深 滬
等待開盤 10-10 09:30:00 美东时间
0.4895
+0.042
+9.34%
華盛通- 最 高0.505
- 今 開0.46
- 成交量 393.15万股
- 最 低 0.4067
- 昨 收 0.4477
- 總市值 443.45万
- 52周最高 2.64
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 0.3654
- 委 比 0.00%
- 總股本 905.92万
- 歷史最高 37800.00
- 量 比 1.33
- 振 幅 21.96%
- 歷史最低 0.3654
- 每 手 1
- 風險率 3.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
Theriva Biologics will present next-generation cancer treatments, VCN-12 and VCN-01, showcasing enhanced antitumor effects and intracranial application potential at the 32nd ESGCT Congress in Seville, October 7-10, 2025.
10-06 12:00
Theriva Biologics Restructures, Cuts Workforce by 32%
Theriva Biologics ( ($TOVX) ) has issued an update. On September 28, 2025, Ther...
10-03 04:39
Theriva Biologics Cuts 32% Of Workforce In Restructuring To Focus On Cancer Drug Development And Regulatory Strategy; Expects Will Extend Its Cash Runway Into Q2 Of 2026
Item 2.05 Costs Associated with Exit or Disposal Activities. On September 28, 2025, the Board of Directors of Theriva Biologics, Inc. (the "Company") approved a plan to resize and restructure the Company (the
10-03 04:04
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodesix (NASDAQ:BDSX) shares increased by 21.6% to $0.52 during Wedne...
09-04 05:06
Theriva Biologics Has Received A Notice Of Allowance For A U.S. Patent Titled "ALKALINE PHOSPHATASE FORMULATIONS (FOR THE TREATMENT OF MICROBIOME-RELATED DISEASES)".
https://patentcenter.uspto.gov/applications/18744950/ifw/docs
09-04 03:58
Theriva Biologics Q2 EPS $(1.93) Misses $(1.08) Estimate
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.08) by 78.7 percent. This is a 82 percent increase over losses of $(10.72) per share from
08-11 20:14
Theriva Biologics GAAP EPS of -$1.93
Theriva Biologics press release (NYSE:TOVX): Q2 GAAP EPS of -$1.93. Cash and cash equivalents of $12.1 million as of June 30, 2025, expected cash runway into Q1 2026 More on Theriva Biologics Seeking ...
08-11 20:03
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
Theriva Biologics Sets 2025 Shareholder Meeting Date
Theriva Biologics ( ($TOVX) ) just unveiled an announcement. Theriva Biologics,...
06-26 04:41
Theriva Biologics To Present Data From VCN-01 Retinoblastoma Phase 1 Clinical Trial At ASCO 2025; Announces Investigator Meeting To Review Topline Data From VIRAGE Phase 2b Trial Of VCN-01 In Metastatic Pancreatic Cancer
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual
05-27 20:08
